Kevin Melody

Kevin Melody

Auto-generated profile, based on publicly available information

Kevin Melody

Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
CWCourtney Woolsey
Courtney Woolsey
VBViktoriya Borisevich
Viktoriya Borisevich
APAbhishek Prasad
Abhishek Prasad
KAKrystle N. Agans
Krystle N. Agans
DDDaniel J. Deer
Daniel J. Deer
RCRobert W. Cross
Robert W. Cross

15 August 2016 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
SSSteven J. Smith
Steven J. Smith
GPGary T. Pauly
Gary T. Pauly
AAAamir Akram
Aamir Akram
KMKevin Melody
Kevin Melody
ZAZandrea Ambrose
Zandrea Ambrose
SHStephen Hughes
Stephen Hughes
Background: Rilpivirine (RPV) is the latest non-nucleoside reverse transcriptase inhibitor (NNRTI) to be approved by Food and Drug Administration to combat HIV-1 infections. NNRTIs inhibit the chemical step in viral DNA synthesis by binding to an allosteric site located about 10 Å from the polymerase active site of reverse transcriptase (RT). Although NNRTIs potently inhibit the replication of wild-type HIV-1, the binding site is not conserved, and mutations arise in the binding pocket. Doravirine (DOR) is a new NNRTI in phase III clinical trials. Methods: Using a single round HIV-1 infection assay, we tested RPV and DOR against a broad panel of NNRTI-resistant mutants to determine their respective activities. We also used molecular modeling to determine if the susceptibility profile of each compound was related to how they bind RT. Results: Several mutants displayed decreased susceptibility to DOR. However, with the exception of E138K, our data suggest that the mutations that reduce the potency of DOR and RPV are non-overlapping. Thus, these 2 NNRTIs have the potential to be used together in combination therapy. We also show that the location at which DOR and RPV bind with the NNRTI binding pocket of RT correlates with the differences in their respective susceptibility to the panel of NNRTI-resistance mutations. Conclusions: This shows that (1) DOR is susceptible to a number of well-known NNRTI resistance mutations and (2) an understanding of the mutational susceptibilities and binding interactions of NNRTIs with RT could be used to develop pairs of compounds with non-overlapping mutational susceptibilities.

17 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
CWCourtney Woolsey
Courtney Woolsey
VBViktoriya Borisevich
Viktoriya Borisevich
APAbhishek Prasad
Abhishek Prasad
KAKrystle N. Agans
Krystle N. Agans
DDDaniel J. Deer
Daniel J. Deer
RCRobert W. Cross
Robert W. Cross
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an unprecedented global pandemic of COVID-19. Animal models are urgently needed to study the pathogenesis of COVID-19 and to screen candidate vaccines and treatments. Nonhuman primates (NHP) are considered the gold standard model for many infectious pathogens as they usually best reflect the human condition. Here, we show that African green monkeys support a high level of SARS-CoV-2 replication and develop pronounced respiratory disease that may be more substantial than reported for other NHP species including cynomolgus and rhesus macaques. In addition, SARS-CoV-2 was detected in mucosal samples of all animals including feces of several animals as late as 15 days after virus exposure. Importantly, we show that virus replication and respiratory disease can be produced in African green monkeys using a much lower and more natural dose of SARS-CoV-2 than has been employed in other NHP studies.

20 September 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
JSJasmine Samal
Jasmine Samal
SKSamantha Kelly
Samantha Kelly
ANAli Na-Shatal
Ali Na-Shatal
AEAbdallah Elhakiem
Abdallah Elhakiem
ADAntu Das
Antu Das
MBMoses Bility
Moses Bility
A major pathogenic feature associated with HIV infection is lymphoid fibrosis, which persists during antiretroviral therapy (ART). Lymphoid tissues play critical roles in the generation of antigen-specific immune response, and fibrosis disrupts the stromal network of lymphoid tissues, resulting in impaired immune cell trafficking and function, as well as immunodeficiency. Developing an animal model for investigating the impact of HIV infection–induced lymphoid tissue fibrosis on immunodeficiency and immune cell impairment is critical for therapeutics development and clinical translation. Said model will enable in vivo mechanistic studies, thus complementing the well-established surrogate model of SIV infection–induced lymphoid tissue fibrosis in macaques. We developed a potentially novel human immune system–humanized mouse model by coengrafting autologous fetal thymus, spleen, and liver organoids under the kidney capsule, along with i.v. injection of autologous fetal liver–derived hematopoietic stem cells, thus termed the BM-liver-thymus-spleen (BLTS) humanized mouse model. BLTS humanized mouse model supports development of human immune cells and human lymphoid organoids (human thymus and spleen organoids). HIV infection in BLTS humanized mice results in progressive fibrosis in human lymphoid tissues, which was associated with immunodeficiency in the lymphoid tissues, and lymphoid tissue fibrosis persists during ART, thus recapitulating clinical outcomes.

1 July 2008 in Journal of Food Protection
Verified
Journal Article
Closed access
KMKevin Melody
Kevin Melody
RSReshani Senevirathne
Reshani Senevirathne
MJMarlene Janes
Marlene Janes
LJLee Ann Jaykus
Lee Ann Jaykus
JSJohn Supan
John Supan
The focus of this research was to investigate the efficacy of icing as a postharvest treatment for reduction of the levels of Vibrio vulnificus and Vibrio parahaemolyticus in commercial quantities ...

27 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRobert W. Cross
Robert W. Cross
ZBZachary A. Bornholdt
Zachary A. Bornholdt
APAbhishek Prasad
Abhishek Prasad
JGJoan B. Geisbert
Joan B. Geisbert
VBViktoriya Borisevich
Viktoriya Borisevich
Thomas W GeisbertThomas W Geisbert
Thomas W Geisbert
A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and humans when administered therapeutically. Uncertainty exists regarding the efficacy of postexposure antibody treatments in the event of a known exposure of a recent rVSV-ZEBOV vaccinee. Here, we model a worst-case scenario using rhesus monkeys vaccinated or unvaccinated with the rVSV-ZEBOV vaccine. We demonstrate that animals challenged with a uniformly lethal dose of EBOV one day following vaccination, and then treated with the anti-EBOV GP mAb MIL77 starting 3 days postexposure show no evidence of clinical illness and survive challenge. In contrast, animals receiving only vaccination or only mAb-based therapy become ill, with decreased survival compared to animals vaccinated and subsequently treated with MIL77. These results suggest that rVSV-ZEBOV augments immunotherapy.